My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 11 of the 22 sources its claims cite were checked for support.
Abstract
BACKGROUND: Migraine is associated with many debilitating symptoms that affect daily functioning. My Migraine Voice is a large global cross-sectional study aimed at understanding the full burden and impact of migraine directly from patients suffering from ≥4 monthly migraine days (MMDs) with a history of prophylactic treatment failure. METHODS: This study was conducted worldwide (31 countries across North and South Americas, Europe, the Middle East and Northern Africa, and the Asia-Pacific region) using an online survey administered to adults with migraine who reported ≥4 MMDs in the 3 months preceding survey administration, with pre-specified criteria of 90% having used preventive migraine treatment (80% with history of ≥1 treatment failure). Prophylactic treatment failure was defined as a reported change in preventive medication by individuals with migraine for any reason, at least once. RESULTS: In total, 11,266 individuals participated in the survey. Seventy-four percent of the participants reported spending time in darkness/isolation due to migraine (average: 19 h/month). While 85% of all respondents reported negative aspects of living with migraine (feeling helpless, depressed, not understood), sleeping difficulties (83%), and fear of the next attack (55%), 57% shared ≥1 positive aspect (learning to cope, becoming a stronger person). Forty-nine percent reported feeling limited in daily activities throughout all migraine phases. Migraine impact on professional, private, or social domains was reported by 87% of respondents (51% in all domains). In the previous 12 months, 38% of respondents had visited the emergency department (average: 3.3 visits), whereas 23% stayed in hospital overnight (average: 3.2 nights) due to migraine. CONCLUSIONS: The burden of migraine is substantial among this cohort of individuals with at least 4 migraine days per month and for whom at least 1 preventive migraine treatment had failed. Interestingly, respondents reported some positive aspects in their migraine journey; the greater resilience and strength brought on by coping with migraine suggests that if future treatments could address existing unmet needs, these individuals with migraine will be able to maximize their contribution to society.
Overview
CoChat Summary
## TL;DR
My Migraine Voice was a 31-country online cross-sectional survey of 11,266 adults with migraine and at least 4 monthly migraine days, designed to measure the burden of migraine, especially among people with prior preventive treatment failure. The study found substantial personal, social, work, and healthcare burden, including 74% spending time in darkness/isolation, 87% reporting impact on professional/private/social domains, and 38% visiting the emergency department in the prior 12 months.
## Key findings
- Among 11,266 participants, 74% reported spending time in darkness/isolation due to migraine, averaging 19 h/month; 83% reported sleeping difficulties and 55% feared the next attack.
- Migraine affected professional, private, or social domains in 87% of respondents, and 51% reported impact in all three domains.
- In the previous 12 months, 38% visited the emergency department for migraine (average 3.3 visits) and 23% stayed in hospital overnight (average 3.2 nights).
- Work burden was substantial: among employed respondents, migraine led to 13% reduction in working time and 48% impairment while working; 52% reported impairment in overall work productivity and daily activities.
## Methods
- Large cross-sectional, multi-country online survey of adults (≥18 years) with migraine in 31 countries across the Americas, Europe, the Middle East and Northern Africa, and Asia-Pacific.
- Eligibility required self-reported migraine with ≥4 monthly migraine days in the prior 3 months; prespecified quotas targeted prior preventive treatment exposure, with 90% reporting current or previous preventive use and 80% of those having switched preventive treatment; 11,266 people participated.
- The survey contained 88 questions and assessed sociodemographics, migraine characteristics, quality of life, daily activities, treatment experience, healthcare use, and work productivity; analyses were descriptive with subgroup comparisons by treatment-failure history using frequencies, means/medians, SDs, t-tests, and chi-square tests.
## Limitations
- The paper states that the sample does not fully mirror the general migraine population; recruitment bias may affect estimates, and people with 1–3 monthly migraine days, those without internet access, and those outside the recruitment catchment were not included.
- The study relied on self-reported diagnoses, healthcare use, and other variables, so these could not be clinically confirmed.
- The text indicates that pooling data across countries may introduce variability, and the cross-sectional design means no longitudinal follow-up; these are evident from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
3 Valid · 0 Not valid · 4 Not checked · 71 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, no detailed assessment of the current treatment pathway, impact on work productivity, or burden associated with premonitory and postdromal phases of migraine is available in individuals experiencing ≥4 MMDs who have had previous prophylactic treatments that failed and continue to experience frequent migraines.”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Background
What the sources say
- Not checked yetcites [4] Buse DC, Manack AN, Fanning KM et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American migraine prevalence and prevention study. Headache 52(10):1456–1470 source
- Could not verifycites [5] Payne KA, Varon SF, Kawata AK et al (2011) The international burden of migraine study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 31(10):1116–1130 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses lost work and treatment costs in migraine generally, and the Methods (page unavailable) describe collecting medication-use and healthcare-utilization data. Neither section establishes that detailed assessments are unavailable for people with ≥4 monthly migraine days after failed prophylactic treatments. Searches for treatment failure and premonitory or postdromal burden found no passage addressing that specific evidence gap. (LLM, conf=0.76)
- Could not verifycites [6] Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain. 13:361–378 sourceExperimental — accuracy not yet measured
The Introduction and Methods (pages unavailable) discuss migraine prophylaxis and record healthcare use and medications, while the Discussion addresses economic burden in chronic versus episodic migraine. Searches for premonitory and postdromal phases, work productivity, treatment pathways, and failed prophylactic treatments found no passage assessing—or asserting the absence of assessments for—the specified ≥4-MMD population. (LLM, conf=0.75)
- Not checked yetcites [7] Blumenfeld A, Varon SF, Wilcox TK et al (2011) 2011. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study. Cephalalgia 31(3):301–305 source
- Partly supportedcites [8] Adams AM, Serrano D, Buse DC et al (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35(7):563–578 sourceExperimental — accuracy not yet measured
The Background (page unavailable) describes barriers to effective migraine diagnosis and treatment as largely uninvestigated, supporting a general gap in knowledge about care. It does not establish the claimed absence of detailed assessments of work productivity or premonitory and postdromal burden specifically among people with ≥4 monthly migraine days and failed prophylactic treatments. (LLM, conf=0.76)
- Could not verifycites [9] Andrée C, Stovner LJ, Steiner TJ et al (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12:541–549 sourceExperimental — accuracy not yet measured
The Introduction and Discussion describe a broad European headache survey, including its plans to assess work and productivity, but do not say whether detailed assessments were unavailable for the subgroup in the claim. A search for failed prophylactic treatment, ≥4 monthly migraine days, and premonitory or postdromal burden found no passage addressing that gap. (LLM, conf=0.72)
- Could not verifycites [10] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the current understanding of migraine burden among individuals with the highest unmet needs, specifically those experiencing ≥4 monthly migraine days (MMDs) and prior prophylaxis failure, is limited.”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Background
What the sources say
- Not checked yetcites [4] Buse DC, Manack AN, Fanning KM et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American migraine prevalence and prevention study. Headache 52(10):1456–1470 source
- Partly supportedcites [5] Payne KA, Varon SF, Kawata AK et al (2011) The international burden of migraine study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 31(10):1116–1130 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says studies comprehensively assessing the burden of chronic migraine are lacking, supporting a general knowledge gap. It does not identify people with ≥4 monthly migraine days and prior prophylaxis failure as the group with limited evidence; its Methods instead classify participants by a threshold of 15 headache days per month. (LLM, conf=0.84)
- Could not verifycites [6] Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain. 13:361–378 sourceExperimental — accuracy not yet measured
The Methods classify participants as episodic or chronic by headache frequency, and the Discussion describes the greater burden of chronic migraine. Neither passage addresses whether understanding is limited for people with ≥4 monthly migraine days and prior prophylaxis failure; searches for that subgroup, treatment failure, and an evidence gap found no such statement in our copy. (LLM, conf=0.73)
- Not checked yetcites [7] Blumenfeld A, Varon SF, Wilcox TK et al (2011) 2011. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study. Cephalalgia 31(3):301–305 source
- Could not verifycites [8] Adams AM, Serrano D, Buse DC et al (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35(7):563–578 sourceExperimental — accuracy not yet measured
The Background distinguishes episodic from chronic migraine at 15 headache days per month and says their burden has been well characterized. The Discussion identifies gaps in particular aspects of migraine care, but our copy does not address whether understanding of burden is limited specifically for people with ≥4 monthly migraine days and prior prophylaxis failure (searched those terms and preventive-treatment failure). (LLM, conf=0.72)
- Partly supportedcites [9] Andrée C, Stovner LJ, Steiner TJ et al (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12:541–549 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says knowledge of the scope and scale of headache burden in Europe is incomplete, which supports the general claim of limited understanding. It does not identify people with ≥4 monthly migraine days and prior prophylaxis failure as a group with particularly limited evidence; searches for those criteria found no supporting passage. (LLM, conf=0.85)
- Could not verifycites [10] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602 sourceExperimental — accuracy not yet measured
The Results section on global causes of disability reports migraine’s overall YLD ranking, while the Discussion’s data-gaps section addresses gaps across diseases generally; neither assesses knowledge of burden in the specified migraine subgroup (page numbers unavailable). Searches for monthly migraine days and prior prophylaxis failure found no passage addressing that subgroup or the claimed limitation. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings are consistent with the results of the IBMS study, which found that for each of the five European countries studied, chronic migraine (per ICHD-2 criteria, persons with ≥15 MMDs) was associated with additional healthcare costs attributable to an increased use of medical services and associated cost [6].”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Discussion
What the sources say
- Partly supportedcites [6] Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain. 13:361–378 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When asked how they felt about living with migraine, overall 85% of respondents (88% of those with ≥2 TFs) reported at least 1 negative aspect of living with migraine.”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Results > Living with migraine
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Per the predefined inclusion criteria, approximately 90% of participants (n = 9856) had taken preventive medication (past or present) for migraine, and ≥ 80% of these (n = 7678) had experienced at least 1 or more TF, which represents 68% of the total survey population (Fig. 1).”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Results
plainn = 7,678- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Per the predefined inclusion criteria, approximately 90% of participants (n = 9856) had taken preventive medication (past or present) for migraine, and ≥ 80% of these (n = 7678) had experienced at least 1 or more TF, which represents 68% of the total survey population (Fig. 1).”
§ My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed > Results
Reported 7678 · recomputed 7884.8
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., & Katsarava, Z. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0846-2 · Cited by 642
Blumenfeld, A., Varon, S., Wilcox, T., Buse, D., Kawata, A., Manack, A., Goadsby, P., & Lipton, R. (2011) · Cephalalgia · doi:10.1177/0333102410381145 · Cited by 627
Buse, D. C., Manack, A. N., Fanning, K. M., Serrano, D., Reed, M. L., Turkel, C. C., & Lipton, R. B. (2012) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2012.02223.x · Cited by 549
Blumenfeld, A. M., Bloudek, L. M., Becker, W. J., Buse, D. C., Varon, S. F., Maglinte, G. A., Wilcox, T. K., Kawata, A. K., & Lipton, R. B. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12055 · Cited by 380
Sackett, D. L., & Wennberg, J. E. (1997) · BMJ · doi:10.1136/bmj.315.7123.1636 · Cited by 368
Bloudek, L. M., Stokes, M., Buse, D. C., Wilcox, T. K., Lipton, R. B., Goadsby, P. J., Varon, S. F., Blumenfeld, A. M., Katsarava, Z., Pascual, J., et al. (2012) · The Journal of Headache and Pain · doi:10.1007/s10194-012-0460-7 · Cited by 339
Self-citationAdams, A. M., Serrano, D., Buse, D. C., Reed, M. L., Marske, V., Fanning, K. M., & Lipton, R. B. (2015) · Cephalalgia · doi:10.1177/0333102414552532 · Cited by 305
Payne, K. A., Varon, S. F., Kawata, A. K., Yeomans, K., Wilcox, T. K., Manack, A., Buse, D. C., Lipton, R. B., Goadsby, P. J., & Blumenfeld, A. M. (2011) · Cephalalgia · doi:10.1177/0333102411410610 · Cited by 74
Research works printed but not linked: 2
- Ruiz de la Torre E, Martelletti P, Craven A et al (2017) Real-world patient perspective on the burden and impact of migraine. Presented at: Congress of the International Headache Society, Vancouver; September 7–10, [Poster #PO-02-184]
- Ruiz de la Torre E, Martelletti P, Craven A et al (2017) Burden and impact of migraine: a caregiver’s perspective. Presented at: Congress of the International Headache Society, Vancouver September 7–10, [Poster #PO-02-185]
Cited by
Buse, D. C., Fanning, K. M., Reed, M. L., Murray, S., Dumas, P. K., Adams, A. M., & Lipton, R. B. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13613 · Cited by 311
“Similarly, the global My Migraine Voice survey assessed the real-world burden and impact of migraine among people with at least 4 migraine days per month in the previous 3 months for whom preventive treatments had failed, and found positive correlations between the number of medication failures and disease burden.(16)…”
BackgroundInfluentialSelf-citationMulleners, W. M., Kim, B.-K., Láinez, M. J. A., Lanteri-Minet, M., Pozo-Rosich, P., Wang, S., Tockhorn-Heidenreich, A., Aurora, S. K., Nichols, R. M., Yunes-Medina, L., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30279-9 · Cited by 270
Self-citationSacco, S., Braschinsky, M., Ducros, A., Lampl, C., Little, P., van den Brink, A. M., Pozo-Rosich, P., Reuter, U., de la Torre, E. R., Sanchez Del Rio, M., et al. (2020) · The Journal of Headache and Pain · doi:10.1186/s10194-020-01130-5 · Cited by 266
Self-citationGoadsby, P. J., Dodick, D. W., Ailani, J., Trugman, J. M., Finnegan, M., Lu, K., & Szegedi, A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30234-9 · Cited by 230
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace
Shimizu, T., Sakai, F., Miyake, H., Sone, T., Sato, M., Tanabe, S., Azuma, Y., & Dodick, D. W. (2021) · The Journal of Headache and Pain · doi:10.1186/s10194-021-01243-5 · Cited by 188
Metadata
- Authors
- Martelletti, P., Schwedt, T. J., Lanteri-Minet, M., Quintana, R., Carboni, V., Diener, H.-C., Ruiz de la Torre, E., Craven, A., Rasmussen, A. V., Evans, S., Laflamme, A. K., Fink, R., Walsh, D., Dumas, P., & Vo, P.
- Affiliations
- Sapienza University of Rome (IT)
- Mayo Clinic (US)
- University of Duisburg-Essen (DE)
- Glostrup Hospital (DK)
- Novartis (Switzerland) (CH)
- Corresponding author
- Schwedt, Todd J.
- Venue
- The Journal of Headache and Pain
- Published
- 2018-11-27
- Volume
- 19
- Issue
- 1
- Pages
- 115-115
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- PMC
- PMC6755592
- OpenAlex
- W2902418797
- Cited by
- 217
- References
- 11
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 38 · 2023: 26 · 2022: 32 · 2021: 35 · 2020: 43 · 2019: 13 · 2018: 1
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- The Journal of Headache and Pain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novartis Pharma AG (N/A)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Keywords
- migraine, disease burden, sleep disorders, emergency department visits, coping and resilience, patient experience, unmet needs
- MeSH terms
- Adult, Analgesics, Cross-Sectional Studies, Europe, Female, Humans, Male, Middle Aged, Migraine Disorders, Preventive Medicine, Surveys and Questionnaires, Global Health, Cohort Studies, Treatment Failure, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. https://app.cochat.ai/papers/10.1186/s10194-018-0946-z
- The paper
- Martelletti, P., Schwedt, T. J., Lanteri-Minet, M., Quintana, R., Carboni, V., Diener, H.-C., Ruiz de la Torre, E., Craven, A., Rasmussen, A. V., Evans, S., Laflamme, A. K., Fink, R., Walsh, D., Dumas, P., & Vo, P. (2018). My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-018-0946-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
